Soft Impact

Why buysiders are lukewarm on Celgene’s acquisition of Impact

Underwhelmed by the proposed acquisition of Impact Biomedicines Inc. by Celgene Corp. (NASDAQ:CELG), buysiders hope to see the big biotech further expand its revenue base beyond Revlimid lenalidomide through additional deals in the near term.

“Celgene has to address the future Revlimid

Read the full 421 word article

User Sign In